24 July 2015
: Case report
Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Khaled A. AlswatBDEFDOI: 10.12659/AJCR.893821
Am J Case Rep 2015; 16:486-490
Abstract
BACKGROUND: Hyperthyroidism is a common disease that usually responds to the conventional therapy of anti-thyroidal medications (methimazole or PTU) and beta-blocker. Refractory hyperthyroidism is a rare condition in which hyperthyroidism fails to respond to the above therapy. Cholestyramine has been shown to decrease thyroid hormone level when added to the ongoing anti-thyroidal medications.
CASE REPORT: A 52-year-old woman with past medical history of enlarging goiter presented with obstructive symptoms of worsening shortness of breath and snoring. Admission thyroid function test showed mild hyperthyroidism (suppressed TSH, slightly high FT4, and high normal FT3) that worsened after she received a CT scan with contrast and failed to respond to a 3-week course of high-dose dexamethasone, high-dose carbimazole, and up-titrated propranolol. Five days after cholestyramine was added, her FT4 decreased by 30% and normalized after 12 days. The patient underwent total thyroidectomy as definitive treatment for the hyperthyroidism and for the obstructive symptoms.
CONCLUSIONS: Cholestyramine is an effective additional treatment for hyperthyroidism and may be an effective treatment for refractory iodine-induced hyperthyroidism. The possibility of self-remission (natural course) is less likely given the dramatic and rapid response to cholestyramine.
Keywords: Anion Exchange Resins - therapeutic use, Cholestyramine Resin - therapeutic use, Hyperthyroidism - etiology
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946611
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948042
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030